What is the history and controversy surrounding the use of intravenous high-dose vitamin C in cancer therapy? How does it work and what are the potential benefits and risks?

The Discovery and Early Uses of Vitamin C

The discovery and isolation of vitamin C was a pivotal advancement in improving human nutrition. Scurvy, a severe vitamin C deficiency disease characterized by weakness, lethargy, easy bruising and bleeding, was a major problem for sailors on long voyages during the 16th-18th centuries, when access to fresh fruits and vegetables was limited. It wasn’t until 1747 that Scottish naval physician James Lind demonstrated that consuming oranges and lemons could cure and prevent scurvy, which had been the leading cause of naval deaths at the time.

It took nearly two more centuries for scientists to identify the curative substance in citrus fruits as vitamin C. In 1932, Hungarian biochemist Albert Szent-Gyorgyi isolated and identified a 6-carbon carbohydrate, hexuronic acid, as the anti-scurvy factor, renaming it “ascorbic acid” in reference to its anti-scorbutic properties. He later received the Nobel Prize in Physiology and Medicine in 1937 for this discovery.

Vitamin C Deficiency and the Debate over Optimal Dosage

Today, vitamin C is a popular dietary supplement, and scurvy is rare due to improved access to fruits, vegetables, and vitamin supplements. However, a significant number of people, even in developed countries, still suffer from vitamin C deficiency. Approximately 7% of the US population has a plasma vitamin C concentration below the level considered scurvy.

Vitamin C has many essential functions in the body beyond its well-known role as an antioxidant. The optimal dosage required to maximize its health benefits has been a subject of debate since its discovery. Linus Pauling, a renowned chemist and two-time Nobel Prize laureate, strongly advocated for megadose quantities of vitamin C (above 1 g per day) to prevent and treat various illnesses, including the common cold and heart disease. However, mainstream medicine has largely ignored or even ridiculed Pauling’s claims, and this controversy continues today.

The Controversial History of High-Dose Vitamin C in Cancer Treatment

The use of high-dose vitamin C as a cancer therapy is also controversial. Nearly 60 years ago, Toronto physician William McCormick observed that cancer patients often presented with severely low levels of vitamin C in their blood and scurvy-like symptoms, leading him to hypothesize that vitamin C might protect against cancer by increasing collagen synthesis.

In 1972, Scottish surgeon Ewan Cameron extended this theory, proposing that ascorbate could suppress cancer development by inhibiting hyaluronidase, which otherwise weakens the extracellular matrix and enables cancer metastasis. Cameron began treating terminally ill cancer patients with high-dose vitamin C and published a case report of 50 patients, some of whom benefited from the treatment.

The Cameron-Pauling Trials and Ongoing Debate

Encouraged by the results, Cameron teamed up with Linus Pauling to conduct clinical trials involving terminal cancer patients. In 1976, they published a study of 100 patients with terminal cancer treated with ascorbate, comparing their disease progression and survival rates to 1000 retrospective control patients. Although the study had flaws, such as the lack of a placebo-control group, the results suggested that patients treated with vitamin C had improved quality of life and survival.

The Cameron-Pauling trials sparked a widespread debate within the medical community. Mainstream medicine largely dismissed the findings, citing the study’s limitations and the lack of placebo-controlled trials. However, proponents of high-dose vitamin C therapy argued that the results warranted further investigation and that the potential benefits outweighed the risks.

Proposed Mechanisms of Action for High-Dose Vitamin C in Cancer Therapy

The proposed mechanisms by which high-dose vitamin C may be effective in cancer therapy are multifaceted. Vitamin C is known to have antioxidant properties, which can help protect healthy cells from oxidative stress and potentially inhibit tumor growth. Additionally, high concentrations of vitamin C can generate reactive oxygen species, leading to selective toxicity against cancer cells.

Vitamin C may also enhance the effectiveness of certain chemotherapeutic agents and radiation therapy, potentially by improving the delivery of these treatments to the tumor site. Furthermore, vitamin C has been shown to modulate the immune system, which could contribute to its anti-cancer effects.

Current Research and Clinical Trials

Despite the ongoing controversy, researchers continue to investigate the potential benefits of high-dose vitamin C in cancer therapy. Several clinical trials are currently underway, exploring the use of intravenous vitamin C in combination with standard cancer treatments, as well as evaluating its effects on quality of life, symptom management, and survival outcomes.

The results of these trials will be crucial in determining the true efficacy and safety of high-dose vitamin C in cancer treatment. As the research continues, the medical community will need to weigh the potential benefits against the risks and limitations, ultimately reaching a consensus on the appropriate role, if any, of this controversial therapy.

Conclusion

The use of high-dose intravenous vitamin C in cancer therapy has a long and contentious history, marked by both promise and skepticism. While the proposed mechanisms suggest potential benefits, the overall evidence remains inconclusive, and the debate within the medical community persists. As research continues, the future of this controversial approach will depend on the outcome of well-designed, placebo-controlled clinical trials that can reliably evaluate its efficacy and safety.

Intravenous High-Dose Vitamin C in Cancer Therapy

January 24, 2020,
by Lewis Cantley and Jihye Yun

Lewis Cantley received his Ph.D. from Cornell University and did his post-doctoral work at Harvard University. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School in Boston. He is current the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. Jihye Yun received her Ph.D. from Johns Hopkins University, School of Medicine under the mentorship of Bert Vogelstein and did her post-doctoral work with Lewis Cantley at Weill Cornell Medicine. She is currently an Assistant Professor and a CPRIT scholar at Baylor College of Medicine in Houston. 

The discovery and isolation of vitamin C was one of the most important advances in improving human nutrition. Scurvy, a severe vitamin C deficiency disease characterized by weakness, lethargy, easy bruising and bleeding, was particularly problematic for sailors on long voyages during the 16th century, where access to fresh fruits and vegetables was limited. In fact, scurvy was the leading cause of naval deaths between the 16th and 18th centuries, killing more sailors than all battles, storms and other diseases combined. It wasn’t until 1747 that Scottish naval physician James Lind demonstrated that consuming oranges and lemons cured and prevented scurvy. However, it took scientists nearly two more centuries to identify the nature of the curative substance contained in citrus fruits, now commonly known as vitamin C. The search for this elusive substance ended in 1932 when Albert Szent-Gyorgyi, a Hungarian biochemist, isolated and identified a 6-carbon carbohydrate, hexuronic acid, as the anti-scurvy factor. Shortly thereafter, Szent-Gyorgyi renamed it “a-scorbic acid”, a reference to its anti-scorbutic properties, and later went on to receive the Nobel Prize in Physiology and Medicine in 1937 for his discoveries. 

Today vitamin C is a popular dietary supplement, and due to improved accessibility to fruits, vegetables and vitamin supplements, disability and death from scurvy are rare. However, it is worth noting that a significant number of people even in developed countries are still vitamin C deficient. For example, approximately 7% of the US population has a plasma vitamin C concentration of less than 11 μM, that is considered scurvy. Vitamin C has many essential functions in our body in addition to its well-known role as an antioxidant. Thus, prolonged periods of sub-optimal vitamin C exposure could have adverse health effects, including an increased susceptibility to a plethora of diseases. In fact, the optimal dosage of vitamin C required to maximize its health benefits has been hotly debated ever since its discovery a century ago. Linus Pauling, a world-renowned chemist and two-time Nobel Prize Laureate, strongly advocated that megadose quantities of vitamin C (above 1 g intake per day) would prevent and treat many illnesses including the common cold and heart diseases. However, mainstream medicine has largely ignored or even ridiculed Pauling’s claim. This controversy is still very much alive today.

The controversial history of high-dose vitamin C in cancer treatment

Utilizing high doses of vitamin C as a cancer therapy is no exception to this controversy. Nearly 60 years ago Toronto physician William McCormick observed that cancer patients often presented with severely low levels of vitamin C in their blood and featured scurvy-like symptoms, leading him to postulate that vitamin C might protect against cancer by increasing collagen synthesis. In 1972, extending this theory, Ewan Cameron, a Scottish surgeon, hypothesized that ascorbate could suppress cancer development by inhibiting hyaluronidase, which otherwise weakens the extracellular matrix and enables cancer to metastasize. He began treating terminally ill cancer patients and published a case report of 50 patients in which some of the treated patients benefited from high dose vitamin C. 

Encouraged by the result, Cameron teamed up with Linus Pauling to conduct clinical trials involving terminal cancer patients. In 1976, they published a study of 100 patients with terminal cancer treated with ascorbate. Their disease progression and survival rates were compared to 1000 retrospective control patients who were matched with the vitamin C-treated patients regarding age, sex, type of cancer and clinical stage and who were treated by the same physicians in the same hospital, and in the same way except that they did not receive vitamin C. Although the study was not well designed by modern standards, mainly because they lacked the placebo-control group, the results demonstrated that patients treated with vitamin C had improved quality of life and a four-fold increase in their mean survival time. In a follow up study, Cameron and Pauling reported that 22% of vitamin C-treated cancer patients survived for more than one year compared to only 0.4% of control patients. A clinical trial in Japan independently showed a similar result. With these promising outcomes, interest in the potential of vitamin C for cancer therapy grew. However, double-blind randomized clinical trials directed by Charles Moertel of the Mayo Clinic failed to show any positive effects of high dose vitamin C in cancer patients, as reported in two papers in the journal of New England Journal of Medicine. Because the Mayo Clinic’s clinical trials were conducted more rigorously, people trusted the Mayo Clinic’s data and discredited the Cameron-Pauling trials, dampening the enthusiasm for vitamin C as a cancer therapy. 

So why did the Pauling and Mayo Clinic trials have different results? There are at least two crucial differences. First, the Mayo Clinic trials abruptly stopped the ascorbate administration, switching to traditional chemotherapy, when the patient developed signs of tumor progression. Thus, the overall median time of vitamin C treatment under the Mayo Clinic trials was only 2.5 months, while the Pauling and Cameron trials treated patients for the duration of the entire study period or as long as 12 years. Secondly, the Mayo Clinic trials administered 10 g of daily ascorbate to patients only orally, while the Cameron and Pauling trials administered their vitamin C both orally and intravenously. This difference in the two dosage routes proved highly consequential.

Rekindling vitamin C cancer therapy: oral vs intravenous administration  

Based on studies pioneered by Mark Levine’s group at the NIH in the 2000s, the oral vitamin C doses used in the Mayo Clinic studies would have produced peak plasma concentration of less than 200 μM. In contrast, the same dose given intravenously, as used in the Pauling studies, would produce peak plasma concentrations of nearly 6 mM, more than 25 times higher. When given orally, vitamin C concentration in human plasma is tightly controlled by multiple mechanisms acting together: intestinal absorption, tissue accumulation, renal reabsorption and excretion, and potentially even the rate of utilization. However, when ascorbate is administered intravenously or intraperitoneally the tight controls are bypassed, and pharmacologic millimolar plasma concentrations of vitamin C can easily be achieved. For example, a phase I clinical study revealed that ascorbate concentrations could safely reach 25-30 mM with intravenous infusion of 100 g of vitamin C. In this study, plasma concentrations around 10 mM were sustained for at least 4 hours which, based on preclinical studies, is sufficient to kill cancer cells. Given the fact that cancer patients were only treated with vitamin C orally in the Mayo Clinic studies, the studies do not disprove high dose vitamin C’s efficacy as a cancer treatment. 

This new knowledge has rekindled interest and spurred new research into the clinical potential of vitamin C. Consequently, over the past decade, there have been an increased number of phase I/II clinical trials and case reports testing the safety and efficacy of high dose vitamin C as a treatment for various cancer patients as a monotherapy or in combinational therapy. We will not discuss these clinical studies as there are already several reviews on the topic. Virtually all studies show improved quality of life for cancer patients by minimizing pain and protecting normal tissues from toxicity caused by chemotherapy. Additionally, vitamin C showed synergistic effects when combined with radiation and standard chemotherapies. Unfortunately, these studies were not designed as large-scale, randomized controlled trials and thus the efficacy of high dose vitamin C therapy remains to be determined.

Challenges of conducting a randomized controlled trial for vitamin C cancer therapy

There are at least three challenges that have thus far prevented large-scale, randomized controlled trials of vitamin C for cancer therapy. First, vitamin C is not patentable. Therefore, there is no financial incentive for pharmaceutical companies to support vitamin C clinical trials, and those that have been done have largely relied on government grants and small private donations. Second, as discussed above, vitamin C cancer therapy has a long history of controversy. Due to the Mayo clinical studies in the 1980s, many orthodox, mainstream clinicians have a prejudice against vitamin C therapy. Third, although many preclinical studies showed high dose vitamin C could kill cancer cells or retard tumor growth in vivo, vitamin C’s mechanisms of action have not been clear, making it hard to predict the pharmacodynamics, the rational design of combinational therapy, and biomarkers for patient stratification. Fortunately, a growing number of recent and rigorous preclinical studies have begun resolving the third challenge, which may also lead to overcoming the first and second barriers. Mechanistic insights into the action of pharmacological vitamin C will generate more explicit scientific hypotheses and allow clinicians to design better trials to investigate those hypotheses, ultimately leading to a definitive answer to the question: can the pharmacological administration of ascorbate benefit cancer patients? Recently, we discussed the potential mechanisms by which vitamin C may act in cancer patients in Nature Reviews Cancer. Here we will highlight one of the mechanisms discovered by our group that relates to Ras protein. 

High-dose vitamin C therapy for KRAS/BRAF mutant cancers

More than 80 years ago, the biochemist Otto Warburg observed that cancer cells consume more glucose and produce more lactate even in the presence of ample oxygen as compared with normal cells. This phenomenon, called aerobic glycolysis or the Warburg effect, has been exploited for visualizing tumors in the clinical setting by imaging their uptake of the radiolabeled glucose analog, [18F] fluoro-2-deoxyglucose (FDG), via Positron Emission Tomography (PET). Although the exact mechanism by which glucose reprograming contributes to tumorigenesis remains unclear, numerous genetic and pharmacological studies showed that this metabolic switch can be essential for cancer survival and proliferation. Thus, targeting glycolysis may offer cancer patients a more selective strategy to treat cancer. 

More than half of colorectal cancers (CRCs) harbor activating mutations in KRAS or BRAF, yet those cancers are the most refractory to current targeted therapies. Our group and others showed that oncogenic mutations in KRAS or BRAF contribute to the Warburg effect and the addiction to glucose in part by upregulating a glucose transporter, GLUT1, that allows cancer cells to take up glucose efficiently. These data suggest a strategy for targeting KRAS or BRAF mutant cancer by exploiting the selective expression of GLUT1 and the metabolic liability that comes with increased reliance on glycolysis. Indeed, by targeting these unique features in these cancer cells, we recently showed that high dose vitamin C could selectively kill KRAS or BRAF mutant CRC cells.

Interestingly, GLUT1 not only transports glucose but also transports dehydroascorbic acid (DHA), the oxidized form of vitamin C. Subsequently, we observed that CRC cells harboring KRAS or BRAF mutations uniquely increased uptake of DHA via GLUT1 when treated with vitamin C. The increased DHA uptake in mutant cells produced oxidative stress, increasing the level of reactive oxygen species (ROS) in cells because intracellular DHA was rapidly reduced back to vitamin C at the expense of glutathione (GSH), a master antioxidant in cells. In turn, we found that elevated ROS activated poly (ADP-ribose) polymerase (PARP), a DNA repair enzyme, consuming large amounts of cellular NAD+ as its cofactor. The depletion of NAD+ resulted in the inactivation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) because GAPDH requires NAD+ as a cofactor. Inhibiting GAPDH in highly glycolytic KRAS or BRAF mutant cells ultimately led to an energy crisis and cell death not seen in their KRAS and BRAF wild-type counterparts. Finally, we showed that high-dose vitamin C therapy reduced both the number and size of tumors in KRAS or BRAF mutant mice as compared to mice without these mutations, confirming that vitamin C selectively targets KRAS or BRAF mutant tumors in mouse models of colon tumors. In short, ascorbate functions as a “Trojan horse” through its conversion to DHA, and insidiously enters cancer cells via GLUT1 to promote the generation of intracellular ROS, which ultimately kills the cancer cell.

Although our study showed that DHA is the pharmaceutically active agent, reduced ascorbate (not directly DHA) is used for preclinical and clinical anti-cancer studies because ascorbate has a significantly longer plasma half-life than DHA (>60 min vs a few min). Moreover, the reduced ascorbate can be efficiently oxidized to DHA in tumors’ extracellular fluids where high level of ROS usually exists. Given that KRAS and BRAF mutations are not only restricted to colorectal cancer, vitamin C may be benefit other types of tumors. For example, 90% of pancreatic cancers and approximately 30% of lung cancers have KRAS mutations. These KRAS mutant tumors also have high GLUT1 expression and are linked to altered glucose metabolism similar to CRC. Therefore, high dose vitamin C may benefit other types of tumors harboring KRAS/BRAF mutations. Based on these results, Weill Cornell Medicine is currently conducting a Phase II clinical trial to examine the effects of intravenous high dose vitamin C in the treatment of KRAS-mutant cancers, and Sun Yat-sen University Cancer Center in China are conducting placebo-controlled, randomized Phase III clinical trials in colorectal cancer patients in combination of chemotherapy. 

While KRAS and BRAF mutations are certainly two of the most frequently mutated oncogenes in human cancer, they are not the only mutations known to affect glucose metabolism and sensitivity towards ascorbate therapy. For example, we and others have found that renal cancer cells (RCC) with loss of VHL (Von Hippel-Lindau), a tumor suppressor that destabilizes HIF1A via ubiquination, are significantly sensitive to ascorbate treatment compared to VHL-proficient cells. RCC-VHL null cells have increased HIF1A transcriptional activity, which not only increases GLUT1 expression, but also deregulates many other glycolytic enzymes to induce metabolic reprograming. Additionally, cancers with increased levels of DNA damage, such as those that have been treated with radiation or those with mutations in BRCA genes, are more reliant on DNA repair mediated by PARP. Pharmacologic vitamin C might selectively impair such cancers by depriving them of the NAD+ necessary for PARP activity.

Concluding Remarks

Vitamin C as a cancer therapy has had a controversial past. What has been intriguing are small clinical trials that suggest some responses, but with no clear rationale for why cancers should respond to vitamin C or a path forward for explaining which patients are most likely to respond.  Now a growing number of preclinical studies are showing how high-dose vitamin C might benefit cancer patients. Importantly, these preclinical studies provide a clear rationale and potential biomarkers that may help personalize the therapeutic approach and identify patient populations that are likely to respond to high-dose vitamin C therapy. Since the mechanisms of action of vitamin C are becoming better defined, we can propose vitamin C combinations in a more rational, hypothesis-driven manner. In addition, given the current high financial cost of new cancer drugs, it seems rational to improve the effectiveness of current therapies by studying their clinical interactions with vitamin C. In our view, the implementation of this treatment paradigm could provide benefit to many cancer patients.

Acknowledgements 

This work was supported by the US National Institutes of Health (NIH) grant (R35 CA197588), Stand Up to Cancer–American Association for Cancer Research grant (SU2C-AACR-DT22-17), and the Damon Runyon Cancer Research Foundation. Lewis Cantley is a founder and member of the senior advisory boards of Agios Pharmaceuticals and Petra Pharmaceuticals, which are developing novel therapies for cancer. The Cantley laboratory also receives financial support from Petra Pharmaceuticals.

Is IV vitamin C effective against COVID-19? | Linus Pauling Institute

Search Field

Vitamin C, also known as ascorbic acid, is currently making headlines in the fight against COVID-19. Reports say that intravenous (IV) vitamin C may help people suffering from this disease.

Recently, IV vitamin C clinical trials began in China and Italy. Doctors in hard-hit areas of the United States are now reporting using it. Furthermore, IV vitamin C appears in some COVID-19 critical care guidelines, like at the Eastern Virginia Medical School.

Even though using IV vitamin C is nothing new, there is not enough scientific evidence to determine if it works against COVID-19.  Read on for more information.

What is IV vitamin C?

A solution of vitamin C is delivered directly into the bloodstream through a vein, typically in the arm. A physician’s order is required to receive this treatment. It is important to get IV vitamin C only in a clinic or other medical setting.

Why use IV vitamin C?

IV vitamin C goes straight into the bloodstream. Because it skips the stomach and intestines, vitamin C in the blood rises to very high levels and very quickly.

What do we know about IV vitamin C in COVID-19?

The clinical data from IV vitamin C trials will not be available for many months. So far, doctors and researchers cannot tell how effective IV vitamin C is or how it might work.

There is some scientific evidence that IV vitamin C can be useful in the treatment of other infections. Most of the recorded use of IV vitamin C has been in the treatment of cancer.

To be clear: IV vitamin C is not a cure for COVID-19. 

What about vitamin C supplements?

It is hard to compare them. You cannot get blood vitamin C levels nearly as high as IV vitamin C when taking vitamin C supplements. 

Despite label claims, no supplement is equal to IV vitamin C – no matter how much you take or what formula you use.

Can vitamin C supplements help your immune system? Yes, but for different reasons.

Caution: Be careful taking very high doses of vitamin C supplements. They can also cause unwanted side effects such as abdominal cramping and diarrhea.

How might IV vitamin C work in COVID-19 patients?

There are several theories about how IV vitamin C may help treat COVID-19:

• Very high vitamin C levels may create free radicals that destroy viruses and bacteria. Our body’s cells have defenses against these free radicals, but viruses do not.
• Another possibility is IV vitamin C renews the body’s antioxidant protection. Serious infections can use up our body’s vitamin C and other antioxidants very quickly.

Vitamin C is a vital part of the immune system, but there is no reason to think IV vitamin C can boost your immune system beyond normal, healthy status. Daily vitamin C from food or supplements is enough to support healthy immunity.

Is IV vitamin C safe?

IV infusions always require proper administration by a medical professional. Patients need to be screened to make sure it is safe for them. Some conditions might prevent a person from getting IV vitamin C.

From research on vitamin C and cancer, we know that IV vitamin C is safe when medical guidelines are followed.

Conclusions

• Although doctors are using IV vitamin C, there is no published scientific evidence about the use of IV vitamin C in COVID-19. Therefore, we cannot fully evaluate its effectiveness.

• IV vitamin C is not the same as taking vitamin C supplements. Vitamin C supplements may help the immune system, but vitamin C blood levels that are far lower than IV vitamin C.

• The National Cancer Institute provides more information about IV vitamin C that may be helpful if you want to know more about this therapy.

• For more information about vitamin C in the immune system, see the Micronutrient Information Center. 

Authors: Alexander Michels, PhD; Victoria Drake, PhD; Sandra Uesugi, RN, BSN, MS, all from the Linus Pauling Institute at Oregon State University. Contact information here.

Vitamin C Droppers – Ivtherapy Clinic

Vitamin C Droppers – Ivtherapy Clinic

Vitamin C droppers

Vitamin C or ascorbic acid is a water soluble vitamin. Our body cannot synthesize and store it for a long time. We must get it every day from food. It is found in citrus fruits, broccoli, tomatoes, and many other vegetables and fruits. You need vitamin C for growth and tissue repair in all parts of the body.

It helps the body produce collagen, an important protein that is used to regenerate skin cells, cartilage, tendons, ligaments and blood vessels. Vitamin C stimulates all immune processes in the body, is necessary for a quick recovery and protection against various types of infections (an immunity dropper is best suited for this). It is involved in wound healing, absorption of other vitamins as well as iron.

Vitamin C in droppers is completely painless. Each shake contains a larger or smaller dose of this vitamin. For example, a dropper for cleansing the body – contains almost 2 g. You can relax for an hour, receiving this life-giving moisture. After the procedure, you are energized for a whole week!

Vitamin C performs the biological functions of a reductant and coenzyme of some metabolic processes, and is an antioxidant. Antioxidants block damage caused by free radicals, substances that damage DNA. Poor elimination of free radicals from the body over time can contribute to the aging process and the development of diseases such as cancer, heart disease and arthritis. Vitamin C can be taken in the form of tablets, capsules as part of vitamin complexes. Our IVTherapy clinic offers advanced technologies that have been used in Europe and America for a long time.

Vitamin C is found in the following foods:

– broccoli

– bell peppers

– strawberries

– papaya

– Brussels sprouts pineapple

– kiwi

– mango

– citrus.

Now ask yourself how many of these wonderful fruits and vegetables do you eat each day?

Intravenous drips, intravenous injections have more advantages than other forms and provide instant results. The intake of vitamin C through the circulatory system ensures complete absorption of the vitamin by the cells. This individual infusion, bypassing the gastrointestinal tract, will help prevent illness and speed up recovery. Intravenous vitamin C will boost your immune system and keep you safe before or after a long flight, and after physical and mental stress. Vitamin C is present in each of our cocktails as the main ingredient. It will help women to improve the condition of their skin, hair, nails (in a dropper for beauty), and men to feel a surge of energy and strength (in a dropper for athletes)!

02/16/2019

Comments

Leave a comment

Other blog articles

Vitamin therapy for wound healing

Vitamin therapy for vascular health

Intravenous vitamin therapy. Eczema treatment

Vitamin C dropper in Moscow. Clinic Innovation!

Infusion therapy

Do you feel apathy, weakness, constant fatigue, or maybe you have a hard time waking up?

These are often already noticeable manifestations of beriberi. Neither exercise nor coffee will get you out of this state – you urgently need to help the body return the vitamin levels to normal in order to become vigorous and healthy again!

Since childhood, we know how useful vitamin C is for our body and we know that it can be obtained from food, regularly enjoying the taste of citrus fruits, bell peppers, plums, sea buckthorn and many other products.

However, to get rid of beriberi, you must regularly consume food.

Every day, a healthy adult body needs from 65 to 90 mg of Vitamin C. If vitamin deficiency is caused by a recent acute respiratory viral infection or influenza, the norm should be even higher, because we are not talking about maintaining the norm, but about replenishing the deficiency!

They say that 1 lemon or 3-4 oranges is enough to get the daily requirement of Vitamin C. You can also eat kiwi, this fruit is the leader in Vitamin C content.

However, part of the vitamin contained in a healthy and tasty fruit will be destroyed by the acidic environment of gastric juice, and part will enter the bloodstream in a very long and confusing way, being absorbed by the intestinal walls.

The already established trend for vitamin drips is a much shorter path to a healthy life full of energy and sound sleep. Vitamin droppers allow you to deliver an individually calculated dosage of vitamin C immediately into the bloodstream without losing a single milligram to metabolic processes.

VITAMIN DROPS FOR IMMUNITY

Restore immunity with vitamin droppers quickly and easily – come to infusion therapy.

But how do you know if you need vitamin drips?

VITAMIN C DRIVER: INDICATIONS

• beriberi – weakness and apathy, constant fatigue and difficult awakening;
• signs of anemia – weakness, depression, dry and sagging skin, pigmentation, hair loss, frequent SARS and prolonged wound healing;
• recovery from past illnesses, such as influenza and SARS, diseases of the gastrointestinal tract.

Ascorbic acid is the most famous and popular antioxidant involved in redox metabolic processes in the body. Vitamin C improves blood circulation, improves the permeability of the walls of blood vessels for the penetration of oxygen and nutrients. Strengthens the protective properties of the body, restores after diseases, accelerates the healing of wounds and scratches. Participates in the synthesis of collagen and elastin, improving the condition of the skin, reduces the appearance of pigmentation. Participates in the absorption of iron by the body.

VITAMIN DRIPPERS: BENEFITS

Vitamin C is a powerful antioxidant and given intravenously has a greater advantage than other forms and provides instant results. Vitamins through a dropper quickly enter the circulatory system, which ensures complete absorption of vitamin C by cells. This will allow you to strengthen the immune system much faster, restore the body, improve the condition of the skin and hair, and also provide you with a good mood and well-being.

• helps to strengthen the immune system;
• takes part in the synthesis of hormones and collagen;
• accelerates wound healing, removes toxins and heavy metals from the body;
• seals the walls of blood vessels, prevents the deposition of cholesterol.

AFTER VITAMIN DROPS:

• complexion improves
• mood rises (stabilises)
• strength and energy appear
• the mode of wakefulness and sleep is normalized

VITAMIN DRIPPERS: WHAT COURSE

The course of vitamin C droppers is selected individually, based on the level of vitamin C in the patient’s blood set at the time of treatment. On average, the course is from 5 to 10 procedures.

Vitamin droppers can include not only Vitamin C – for each patient, a selection of vitamins and microelements is required, which will comprehensively solve the problem.

Vitamin C in the composition of droppers to solve other problems in the body, enhances the absorption and action of other substances for a more effective result!

Sign up for an integrative consultation or infusion therapy now to start your journey to health, vitality and beauty.

As part of an integrative treatment, INNOVATION Clinic offers to walk the path to beauty through health!

Vitamin C dropper at INNOVATION Clinic:

• Doctors-cosmetologists with higher medical education and regular professional development
• Innovative approach for natural results
• Vitamin C dropper in Moscow at an adequate price without hidden fees
• Full follow-up of the patient after the procedure

Anti-Age Dropper
Dropper Actovegin
Dropper Heptral
Dropper Iron
Cinderella drip
Dropper Cytoflavin
Ethoxydol dropper (for stress)
Reamberin dropper (detox)

Cost of procedures “Innovation Clinic”

Prices for popular services

Service code

Service name

Appointment with a doctor –
cosmetologist

Appointment with a doctor –
cosmetologist Ph.D.